Based on the detected CDKN2A/B deletion, we further tested the potential of the CDK4/6 inhibitor abemaciclib, which showed strong efficacy against both gliosarcoma cell models and entrectinib distinctly synergized with 5 μM abemaciclib in vitro. This evidence concerns the gene CDKN2A and gliosarcoma.